BSPED2024 Poster Presentations Obesity 2 (7 abstracts)
1Alder Hey, Liverpool, United Kingdom; 2NHS England and NHS improvement, London, United Kingdom; 3Evira AB, Triewaldsgrand 2, Stockholm, Sweden; 4Department of Clinical Science, Intervention and Technology, Division of Pediatrics, Karolinska Institute, Huddinge, Sweden
Introduction: Due to the increasing prevalence of childhood obesity, and challenges presented by associated physical and psychological comorbidities, NHS England initiated a pilot to treat Complications from Excess Weight (CEW) in dedicated clinics across the country. Facilitating sufficient face-to-face appointments with increased need for services carries associated costs and greater demand, both on the patient and their families, and on the medical team. To supplement the regular clinical encounters, a digital support system (Evira) designed for daily home weight measurements was introduced into the treatment pathway to provide consistent input from the multidisciplinary team whilst reducing the need for physical visits.
Methods: Patients seen in the Alder Hey CEW clinic between January and June 2024 were offered the opportunity to use the custom-made digitless measuring device as part of their treatment pathway. The device transfers the measurements via Bluetooth to a mobile application and presents BMI Z-scores graphically with an individualised weight loss target curve. Additionally, the data is transferred to a web-based interface that enables the clinic to monitor patient progress as they receive additional input from the multidisciplinary team, and to provide regular contact through the applications communication system.
Results: A cohort of 32 patients were enrolled into the device after discussion and consent from the patient and their families. The average age was 13.6 years. The average BMI standard deviation score (SDS) at the start of treatment was +3.64, with a mean change in the first month of use of -0.043 SDS, a mean change of -0.012 in the second month, and a further change of -0.021 after the third month. During the first month, 100% of patients recorded at least one measurement, with 92% recording at least one by the third month, and on average patients recorded measurements on 3.5 days per week.
Conclusions: Use of regular home measurements alongside a standard treatment pathway can promote greater autonomy amongst the patient population regarding positive changes by providing graphical representation of their progress. Additionally, with continuous data provided to the clinic, adherence to treatment can be tracked and supported on a regular basis especially between clinic appointments.